Morgan Stanley Issues Pessimistic Forecast for Organon & Co. (NYSE:OGN) Stock Price

Organon & Co. (NYSE:OGN - Get Free Report) had its target price dropped by stock analysts at Morgan Stanley from $16.00 to $15.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Morgan Stanley's price target suggests a potential upside of 33.93% from the company's previous close.

Several other equities research analysts have also issued reports on the stock. Barclays lowered their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $20.60.

Organon & Co. Stock Performance

Shares of OGN traded up $0.02 during trading hours on Wednesday, reaching $11.20. 1,432,826 shares of the company traded hands, compared to its average volume of 2,645,215. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The stock's fifty day moving average is $14.64 and its 200 day moving average is $15.64. Organon & Co. has a 1-year low of $10.94 and a 1-year high of $23.10. The stock has a market cap of $2.89 billion, a P/E ratio of 3.36, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73.

Remove Ads

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Equities research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Institutional Trading of Organon & Co.

Several large investors have recently added to or reduced their stakes in OGN. Gilman Hill Asset Management LLC boosted its holdings in shares of Organon & Co. by 2.9% in the 1st quarter. Gilman Hill Asset Management LLC now owns 646,912 shares of the company's stock worth $9,633,000 after acquiring an additional 18,249 shares in the last quarter. RFG Advisory LLC acquired a new position in Organon & Co. in the first quarter worth $362,000. Merit Financial Group LLC acquired a new position in Organon & Co. in the first quarter worth $205,000. Quad Cities Investment Group LLC grew its holdings in shares of Organon & Co. by 31.2% during the first quarter. Quad Cities Investment Group LLC now owns 19,954 shares of the company's stock worth $297,000 after purchasing an additional 4,743 shares during the last quarter. Finally, NBC Securities Inc. increased its stake in shares of Organon & Co. by 111,262.5% in the first quarter. NBC Securities Inc. now owns 8,909 shares of the company's stock valued at $132,000 after buying an additional 8,901 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.